PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced positive results from new tests of the Company’s patented ‘next generation’ anti-cancer compounds, which have demonstrated the ability to kill difficult-to-treat human cancer cells, including colon cancer cells and human glioblastoma cells related to brain cancer, an often fatal form of cancer.
